Inventor · disambiguated record
Mark Winderlich
Also filed as: WINDERLICH MARK
7 granted patents·14 pending applications·45 citations·filing 2011–2024
84Inventor score
Top patents by PatentIndex Score
21 records- 0193US12194095B2Combinations and uses thereofINCYTE CORP·Filed 2021·Granted Jan 14, 2025·2 cites·28 claims
- 0289US8877899B2Anti-CD38 antibody and lenalidomide or bortezomib for the treatment of multipe myeloma and NHLROJKJAER LISA·Filed 2011·Granted Nov 4, 2014·25 cites·19 claims
- 0387US9289490B2Combinations and uses thereofMORPHOSYS AG·Filed 2014·Granted Mar 22, 2016·10 cites·20 claims
- 0485US11224654B2Combinations and uses thereofMORPHOSYS AG·Filed 2016·Granted Jan 18, 2022·2 cites·18 claims
- 0581US10617691B2Combination of an anti-CD19 antibody and a Bruton's tyrosine kinase inhibitor and uses thereofMORPHOSYS AG·Filed 2016·Granted Apr 14, 2020·3 cites·16 claims
- 0681US2025195646A1Combinations and uses thereofINCYTE CORP·Filed 2024·Application pending·0 cites
- 0778US9765152B2Method for the treatment of multiple myeloma or non-Hodgkins lymphoma with anti-CD38 antibody and bortezomib or carfilzomibMORPHOSYS AG·Filed 2016·Granted Sep 19, 2017·2 cites·14 claims
- 0877US2024424012A1Combinations and uses thereofINCYTE CORP·Filed 2024·Application pending·0 cites
- 0977US2024366756A1Combinations and uses thereofINCYTE CORP·Filed 2024·Application pending·0 cites
- 1074US10308722B2Method for the treament of multiple myeloma or non-hodgkins lymphoma with anti-CD38 antibody in combination with thalidomine, lenalidomids, or pomalidomideMORPHOSYS AG·Filed 2017·Granted Jun 4, 2019·1 cites·20 claims
- 1174US2024009196A1Combination of an anti-cd19 antibody and a bruton's tyrosine kinase inhibitor and uses thereofMORPHOSYS AG·Filed 2023·Application pending·0 cites
- 1271US2022283166A1Methods for predicting therapeutic benefit of anti-cd19 therapy in patientsMORPHOSYS AG·Filed 2022·Application pending·0 cites
- 1364US2025186460A1Treatment paradigm for an anti-cd19 antibody and venetoclax combination treatmentINCYTE CORP·Filed 2024·Application pending·0 cites
- 1462US2020206228A1Combination of an anti-cd19 antibody and a bruton's tyrosine kinase inhibitor and uses thereofMORPHOSYS AG·Filed 2020·Application pending·0 cites
- 1562US2020352975A1Combinations and uses thereofMORPHOSYS AG·Filed 2020·Application pending·0 cites
- 1661US2020353077A1Combinations and uses thereofMORPHOSYS AG·Filed 2020·Application pending·0 cites
- 1758US2014255427A1Combination therapy with an anti - cd19 antibody and a nitrogen mustardAMERSDORFFER JUTTA·Filed 2012·Application pending·0 cites
- 1858US2014227277A1Combination therapy with an anti-CD19 antibody and a purine analogAMERSDORFFER JUTTA·Filed 2012·Application pending·0 cites
- 1956US2019195879A1Methods for predicting therapeutic benefit of anti-cd19 therapy in patientsMORPHOSYS AG·Filed 2017·Application pending·0 cites
- 2054US2021292410A1Treatment paradigm for an anti-cd19 antibody and venetoclax combination treatmentMORPHOSYS AG·Filed 2018·Application pending·0 cites
- 2150US2022242952A1Anti-cd19 therapy in patients having a limited number of nk cellsMORPHOSYS AG·Filed 2020·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Mark Winderlich files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →